In vitro and in vivo pharmacological profile of UFP-512, a novel selective δ-opioid receptor agonist; correlations between desensitization and tolerance

British Journal of Pharmacology

Volumn 152, Issue 8, 2007, Pages 1312-1324

  Aguila, B ^a   Coulbault, L ^a   Boulouard, M ^b   Liveilli, F ^a   Davis, A ^a   Toth, G ^c   Borsodi, A ^c   Balboni, G ^d,e   Salvadori, S ^e   Jauzac, P ^a   Allouche, S ^a,f  

^a UNIVERSITÉ DE CAEN   (France)

^b CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Antidepressant like effect; Desensitization; Endocytosis; Human opioid receptor (hDOP receptor); Morphine; Opioid tolerance; Phosphorylation; Trafficking; UFP 512

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UFP 512; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG TOLERANCE; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOOD DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CYTARABINE; DEPRESSION; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; ENDOCYTOSIS; HUMANS; LOMUSTINE; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOXANTRONE; NEUROBLASTOMA; OLIGOPEPTIDES; PHOSPHORYLATION; PREDNISONE; RECEPTORS, OPIOID, DELTA; SIGNAL TRANSDUCTION; SWIMMING;

EID: 36949014094     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707497     Document Type: Article

References (37)

1. Aguila B, Roussel M, Jauzac P, Allouche S (2006). High-purity selection and maintenance of gene expression in human neuroblastoma cells stably over-expressing GFP fusion protein application for opioid receptors desensitization studies. Brain Res 1114: 11-18.
2. Allouche S, Hasbi A, Ferey V, Sola B, Jauzac P, Polastron J (2000). Pharmacological delta1- and delta2-opioid receptor subtypes in the human neuroblastoma cell line SK-N-BE: no evidence for distinct molecular entities. Biochem Pharmacol 59: 915-925.
3. Allouche S, Polastron J, Jauzac P (1996). The delta-opioid receptor regulates activity of ryanodine receptors in the human neuroblastoma cell line SK-N-BE. J Neurochem 67: 2461-2470.
4. Allouche S, Roussel M, Marie N, Jauzac P (1999). Differential desensitization of human delta-opioid receptors by peptide and alkaloid agonists. Eur J Pharmacol 371: 235-240.
5. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W (1995). Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 65: 1636-1645.
6. Balboni G, Salvadori S, Guerrini R, Negri L, Giannini E, Jinsmaa Y et al. (2002). Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem 45: 5556-5563.
7. Belcheva MM, Vogel Z, Ignatova E, Avidor-Reiss T, Zippel R, Levy R et al. (1998). Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem 70: 635-645.
8. Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002). Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) 164: 42-48.
9. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
10. Connor M, Henderson G (1996). delta- and mu-opioid receptor mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br J Pharmacol 117: 333-340.
11. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F et al. (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
12. Finn AK, Whistler JL (2001). Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32: 829-839.
13. Galandrin S, Bouvier M (2006). Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70: 1575-1584.
14. Gutstein HB, Rubie EA, Mansour A, Akil H, Woodgett JR (1997). Opioid effects on mitogen-activated protein kinase signaling cascades. Anesthesiology 87: 1118-1126.
15. Haberstock-Debic H, Kim KA, Yu YJ, von Zastrow M (2005). Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25: 7847-7857.
16. Hasbi A, Allouche S, Sichel F, Stanasila L, Massotte D, Landemore G et al. (2000). Internalization and recycling of delta-opioid receptor are dependent on a phosphorylation-dephosphorylation mechanism. J Pharmacol Exp Ther 293: 237-247.
17. Hasbi A, Polastron J, Allouche S, Stanasila L, Massotte D, Jauzac P (1998). Desensitization of the delta-opioid receptor correlates with its phosphorylation in SK-N-BE cells: involvement of a G protein-coupled receptor kinase. J Neurochem 70: 2129-2138.
18. Jutkiewicz EM (2006). The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6: 162-169.
19. Jutkiewicz EM, Rice KC, Woods JH, Winsauer PJ (2003). Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav Pharmacol 14: 509-516.
20. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L et al. (1996). Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271: 19021-19024.
21. Lecoq I, Marie N, Jauzac P, Allouche S (2004). Different regulation of human delta-opioid receptors by SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide] and endogenous enkephalins. J Pharmacol Exp Ther 310: 666-677.
22. Marie N, Aguila B, Allouche S (2006). Tracking the opioid receptors on the way of desensitization. Cell Signal 18: 1815-1833.
23. Marie N, Landemore G, Debout C, Jauzac P, Allouche S (2003a). Pharmacological characterization of AR-M1000390 at human delta opioid receptors. Life Sci 73: 1691-1704.
24. Marie N, Lecoq I, Jauzac P, Allouche S (2003b). Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists. J Biol Chem 278: 22795-22804.
25. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383: 819-823.
26. Matthes HW, Smadja C, Valverde O, Vonesch JL, Foutz AS, Boudinot E et al. (1998). Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci 18: 7285-7295.
27. Namir N, Polastron J, Allouche S, Hasbi A, Jauzac P (1997). The delta-opioid receptor in SK-N-BE human neuroblastoma cell line undergoes heterologous desensitization. J Neurochem 68: 1764-1772.
28. Pitcher JA, Tesmer JJ, Freeman JL, Capel WD, Stone WC, Lefkowitz RJ (1999). Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J Biol Chem 274: 34531-34534.
29. Polastron J, Mur M, Mazarguil H, Puget A, Meunier JC, Jauzac P (1994). SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors. J Neurochem 62: 898-906.
30. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
31. Shahabi NA, McAllen K, Sharp BM (2003). Phosphorylation of activating transcription factor in murine splenocytes through delta opioid receptors. Cell Immunol 221: 122-127.
32. 3H] H-Tyr-Ticpsi[CH2-NH] Cha-Phe-OH, a highly specific and stable delta-opioid antagonist. Peptides 20: 1079-1083.
33. Trapaidze N, Gomes I, Cvejic S, Bansinath M, Devi LA (2000). Opioid receptor endocytosis and activation of MAP kinase pathway. Brain Res Mol Brain Res 76: 220-228.
34. 2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides, in press.
35. Vergura R, Valenti E, Hebbes CP, Gavioli EC, Spagnolo B, McDonald J et al. (2006). Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides 27: 3322-3330.
36. Zhang J, Ferguson S, Law P, Barak L, Caron M (1999a). Agonist-specific regulation of delta-opioid receptor trafficking by G protein-coupled receptor kinase and beta-arrestin. J Recept Signal Transduct Res 19: 301-313.
37. Zhang Z, Xin SM, Wu GX, Zhang WB, Ma L, Pei G (1999b). Endogenous delta-opioid and ORL1 receptors couple to phosphorylation and activation of p38 MAPK in NG108-15 cells and this is regulated by protein kinase A and protein kinase C. J Neurochem 73: 1502-1509.